Serum concentrations of orosomucoid: Improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease?

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 9, 1997, Pages 933-941

  Kjeldsen, J ^a   Lauritsen, K ^a   Schaffalitzky De Muckadell, O B ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute phase proteins; Crohn's disease; Glucocorticoids; Inflammatory bowel disease; Orosomucoid; Ulcerative colitis

Indexed keywords

ACUTE PHASE PROTEIN; GLUCOCORTICOID; MESALAZINE; OLSALAZINE; OROSOMUCOID; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE REGRESSION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0030771829     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709011205     Document Type: Article

References (45)

1. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
2. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984;86: 249-66.
3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041-8.
4. Lennard-Jones JE, Misiewicz JJ, Connell AM, Baron JH, Jones FA. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965;1:188-9.
5. Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
6. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
7. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
8. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
9. Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77:829-42.
10. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70.
11. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993;104:1293-301.
12. André C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981;22:571-4.
13. Buckell NA, Lennard-Jones JE, Hernandez MA, Kohn J, Riches PG, Wadsworth J. Measurements of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut 1979;20:22-7.
14. Fagan EA, Dyck RF, Maton PN, Hodgson HJF, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982;12:351-9.
15. Brignola C, Iannone P, Belloli C, De Simone G, Bassein L, Gionchetti P, et al. Prediction of relapse in patients with Crohn's disease in remission: a simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastroenterol Hepatol 1994;6:955-61.
16. Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn's disease in the county of Copenhagen, 1962 to 1978. Gastroenterology 1982;83:563-8.
17. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
18. Nielsen H, Petersen PH, Feldt-Rasmussen U, Binder V. Variations in plasma proteins concentrations in individuals with ulcerative colitis: analytical and biological factors. Scand J Clin Lab Invest 1979;39:495-502.
19. Statland BE, Winkel P, Killingsworth LM. Factors contributing to intra-individual variation of serum constituents. VI. Physiological day-to-day variation in concentrations of 10 specific proteins in sera of healthy subjects. Clin Chem 1976;22:1635-8.
20. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89-92.
21. Armitage P, Berry G Statistical methods in medical research. 3rd ed. Oxford: Blackwell Scientific Publications; 1994.
22. Statsoft Inc. Statistica for Windows™ v. 4.3. Tulsa (OK): Statsoft, 1994.
23. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988;10:401-5.
24. Jensen KB, Jarnum S, Koudahl G, Kristensen M. Serum orosomucoid in ulcerative colitis. Its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976;11:177-83.
25. Harris EK, Yasaka T. On the calculation of a 'reference change' for comparing two consecutive measurements. Clin Chem 1983; 29:25-30.
26. Boyd JC, Harris EK. Utility of reference change values for the monitoring of inpatient laboratory data. In: Zinder O, editor. Optimal use of the clinical laboratory. 5th International Meeting: Clinical Laboratory Organization and Management; 1985; Haifa, Israel. Basel: Karger; 1986. p. 111-22.
27. Harris EK, Brown SS. Temporal changes in the concentrations of serum constituents in healthy men. Distribution of within-person variances and their relevance to the interpretation of differences between successive measurements. Ann Clin Biochem 1979;16:169-76.
28. Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993;28:821-6.
29. Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Result of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9:50-4.
30. Truelove SC, Willoughby CP, Lee EG, Kettlewell MGW. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-8.
31. Dickinson RJ, Ashton MG, Axon ATR, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-204.
32. McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Hecketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986;27:481-5.
33. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
34. Modigliani R, Mary J-Y, Simon J-F, Cortot A, Soule J-C, Gendre J-P, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990;98:811-8.
35. Landi B, N'Guyen Anh T, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992; 102:1647-53.
36. Brignola C, De Simone G, Iannone P, Belloli C, Evangelisti A, Campieri M, et al. Influence of steroid treatment's duration in patients with active Crohn's disease. Agents Actions 1992. p. C90-2.
37. Wright JP, Alp MN, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987;32:164-70.
38. Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in the neuroendocrine control and therapy of inflammatory diseases. Mediators Inflam 1993;2:263-70.
39. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
40. Kushner I. Regulation of the acute phase response by cytokines. Perspec Biol Med 1993;36:611-22.
41. Kirkwood BR Essentials of medical statistics. Oxford: Blackwell Scientific Publications; 1988.
42. Saverymuttu SH, Hodgson HJF, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986;27:809-13.
43. Mazlam MZ, Hodgson HJF. Interrelations between interleukin-6, interleukin-1β, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35:77-83.
44. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7.
45. Löfberg R, Danielsson Å, Suhr O, Nilsson Å, Schiöler R, Nyberg A, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713-8.